CoChat

Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes

Open access

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Exenatide treatment improves glycemia in adults with type 2 diabetes and has been shown to reduce postprandial hyperglycemia in adolescents with type 1 diabetes. We studied the effects of exenatide on glucose homeostasis in adults with long-standing type 1 diabetes. RESEARCH DESIGN AND METHODS: Fourteen patients with type 1 diabetes participated in a crossover study of 6 months' duration on exenatide (10 μg four times a day) and 6 months off exenatide. We assessed changes in fasting and postprandial blood glucose and changes in insulin sensitivity before and after each study period. RESULTS: High-dose exenatide therapy reduced postprandial blood glucose but was associated with higher fasting glucose concentrations without net changes in hemoglobin A1c. Exenatide increased insulin sensitivity beyond the effects expected as a result of weight reduction. CONCLUSIONS: Exenatide is a promising adjunctive agent to insulin therapy because of its beneficial effects on postprandial blood glucose and insulin sensitivity in patients with type 1 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc13-1473

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study design and timeline for testing. Twenty patients with long-standing type 1 diabetes were enrolled, 14 completed both treatment periods, and 13 completed two hyperinsulinemic-euglycemic clamp studies at the end of periods A and B. Analyses focused on exenatide treatment. The interaction between exenatide and daclizumab was nonsignificant (P = 0.87); thus, the daclizumab and no-daclizumab groups were combined in the analyses of exenatide.
Figure 1 Study design and timeline for testing. Twenty patients with long-standing type 1 diabetes were enrolled, 14 completed both treatment periods, and 13 completed two hyperinsulinemic-euglycemic clamp studies at the end of periods A and B. Analyses focused on exenatide treatment. The interaction between exenatide and daclizumab was nonsignificant (P = 0.87); thus, the daclizumab and no-daclizumab groups were combined in the analyses of exenatide.CC BY-NC-ND · PubMed Central
Figure 2 Changes in weight (A), insulin dosing (B), fasting and postprandial blood glucose (C), and insulin sensitivity (SI) (D) for each subject off exenatide (open bars) and on exenatide (solid bars). Data are mean ± SD.
Figure 2 Changes in weight (A), insulin dosing (B), fasting and postprandial blood glucose (C), and insulin sensitivity (SI) (D) for each subject off exenatide (open bars) and on exenatide (solid bars). Data are mean ± SD.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 77

Metadata

Authors
Sarkar, G., Alattar, M., Brown, R. J., Quon, M. J., Harlan, D. M., & Rother, K. I.
Affiliations
  • National Institutes of Health (US)
  • University of Maryland, Baltimore (US)
  • UMass Memorial Health Care (US)
Corresponding author
Rother, Kristina I.
Venue
Diabetes Care
Published
2014-02-11
Volume
37
Issue
3
Pages
666-670
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2152918233
Cited by
74
References
14
Citations by year
2026: 3 · 2025: 3 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 6 · 2019: 1 · 2018: 6 · 2017: 11 · 2016: 14 · 2015: 14 · 2014: 6
FWCI
8.91
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK079637)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
exenatide, type 1 diabetes, insulin sensitivity, postprandial blood glucose, fasting blood glucose, glucose homeostasis, GLP-1 receptor agonists, weight loss
MeSH terms
Exenatide, Adult, Blood Glucose, Body Weight, Diabetes Mellitus, Type 1, Drug Administration Schedule, Fasting, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin Resistance, Male, Middle Aged, Peptides, Venoms, Cross-Over Studies, Postprandial Period

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes. https://app.cochat.ai/papers/10.2337/dc13-1473
The paper
Sarkar, G., Alattar, M., Brown, R. J., Quon, M. J., Harlan, D. M., & Rother, K. I. (2014). Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes. Diabetes Care. https://doi.org/10.2337/dc13-1473

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.